Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Scalp cooling significantly reduces hair loss in chemotherapy patients.

This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.

This study reports that FDA-approved scalp cooling caps, like DigniCap and Paxman, can help 50-66% of breast cancer patients retain at least 50% of their hair during chemotherapy, with specific recommendations and limitations discussed for different patient groups.